Managing IP survey: SPC framework

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

Managing IP survey: SPC framework

biotech168

Managing IP is seeking views from in-house counsel at pharma and biotech companies on the state of the SPC framework in Europe; including Article 3a, the waiver and unitary SPCs

biotech200

You can take the survey here. 

Please only take the survey if you are an in-house lawyer from a pharmaceutical, biotech or life sciences company.


We are looking to gain and share insight on how in-house IP counsel view the SPC framework in Europe; including Article 3a, the SPC Manufacturing Waiver and unitary SPCs. 

This is the second in our series of in-house surveys in 2019. You can read the special report on the findings of that survey, on the changing dynamic between artificial intelligence and IP, here.

Don’t miss the chance to have your say.

The survey should take no longer than five minutes to complete, and all responses will only be published in an aggregated and anonymised form. The more responses we get, the more illuminating the final report will be.

If you would like to discuss your thoughts in more detail, please contact Patrick Wingrove at patrick.wingrove@managingip.com

more from across site and SHARED ros bottom lb

More from across our site

Julia Bishop is director of IP at Twilio in the US
Hellberg is an IP director at Essity in Sweden
Palińska is the business & IP law lead at CD Projekt Red in Poland
Teemu Itälä is head of legal and compliance for technology standards at Nokia in Finland
Schwitulla is the head of litigation management at Nokia in Germany
David Degen is senior IP counsel at Novartis, Switzerland
Demetrio Roberto Cavicchia is an IP director at Angelini Pharma in Italy
Almeida is the IP group leader at Bosch in Brazil
Amanda Luz is brand protection manager - global at Adidas in the US
Samantak Ghosh is vice president of IP at Avere Therapeutics in the US
Gift this article